Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 29, 2020 16:54 ET | Source: Immutep Limited

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
December 16, 2020 08:00 ET | Source: Immutep Limited

Immutep Upscales Efti Manufacturing

Sydney, AUSTRALIA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
December 15, 2020 08:00 ET | Source: Immutep Limited

Immutep Operational Update

Efti clinical trial status updatesExcellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 Sydney, AUSTRALIA, Dec. ...
December 09, 2020 17:53 ET | Source: Immutep Limited

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy,...
December 09, 2020 17:14 ET | Source: Immutep Limited

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer

First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune...
November 18, 2020 18:19 ET | Source: Immutep Limited

Immutep Announces Expansion of TACTI-002 Collaboration Trial

Additional 74 patients with 1st line non-small cell lung cancer (NSCLC) to be enrolled, more than tripling patient numbers in this indicationFollows encouraging interim data from 1st line NSCLC...
November 18, 2020 17:59 ET | Source: Immutep Limited

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on...
November 09, 2020 16:10 ET | Source: Immutep Limited

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release...
November 09, 2020 08:00 ET | Source: Immutep Limited

Immutep Announces Australian Patent Grant For IMP701 Antibody

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 2015229103 entitled “Antibody molecules...
November 02, 2020 17:24 ET | Source: Immutep Limited

Immutep’s TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting

SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...